| Literature DB >> 20221426 |
Abstract
The envelope of HSV-1 contains a number of glycoproteins, four of which are essential for virus entry. Virus particles lacking gB, gD, gH or gL are entry-defective, although these viruses retain the ability to bind to the plasma membrane via the remaining glycoproteins. Soluble forms of gD have been shown to trigger the nuclear translocation of the NF-kappaB transcriptional complex in addition to stimulating the production of Type I interferon. By taking advantage of the entry-defective phenotype of glycoprotein-deficient HSV-1 virus particles, the results presented here show that binding of virions to cellular receptors on the plasma membrane is sufficient to stimulate a change in cellular gene expression. Preliminary microarray studies, validated by quantitative real-time PCR, identified the differential expression of cellular genes associated with the NF-kappaB, PI3K/Akt, Jak/Stat and related Jak/Src pathways by virions lacking gB or gH but not gD. Gene induction occurred at a few particles per cell, corresponding to physiological conditions during primary infection. Reporter assay studies determined that NF-kappaB transcriptional activity is stimulated within an hour of HSV-1 binding, peaks between two and three hours post-binding and declines to background levels by five hours after induction. The immediate, transient nature of these signalling events suggests that HSV-1 glycoproteins, particularly gD, may alter the cellular environment pre-entry so as to condition the cell for viral replication.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20221426 PMCID: PMC2832691 DOI: 10.1371/journal.pone.0009560
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fold change in gene expression after inoculation with entry-defective HSV-1.
| Gene | Description | ΔgB | ΔgD | ΔgH |
|
| ||||
| BCL2A1 | hematopoietic BCL2-related protein A1 | −3.85 * | 5.56 | 1.42 |
| BIRC1 | baculoviral IAP repeat-containing 1 | −2.33 | −1.12 | −3.13 ** |
| BIRC2 | baculoviral IAP repeat-containing 2 | 3.85 | 3.98 | 1.72 |
| BIRC3 | baculoviral IAP repeat-containing 3 | 2.88 | 1.00 | 7.71 *** |
| CCL2 | macrophage chemoattractant protein-1 | 2.32 * | 1.34 | 2.13 * |
| LTA | lymphotoxin alpha (TNF superfamily, member 1) | −1.22 | 2.31 | −1.20 |
| NFKB1 | nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) | 2.98 * | −1.92 | 3.09 ** |
| NFKBIA | nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha | −1.19 | 1.23 | 2.54 ** |
| PECAM1 | platelet/endothelial cell adhesion molecule (CD31 antigen) | 4.60 * | 1.00 | 3.09 * |
|
| ||||
| A2M | alpha-2-macroglobulin | 5.07 * | 1.79 | 2.23 |
| CSN2 | casein beta | 5.23 ** | −1.54 | 1.48 |
| CXCL9 | chemokine (C-X-C motif) ligand 9 | 2.22 | −1.59 | 1.06 |
| IRF1 | interferon regulatory factor-1 | 1.90 | −2.94 | 1.00 |
| MMP10 | matrix metallopeptidase 10 | 1.09 | −1.12 | 2.50 |
| NOS2A | nitric oxide synthase 2A | 1.26 | 1.21 | 8.01 ** |
|
| ||||
| BCL2 | B-cell CLL/lymphoma 2 | 3.54 | −1.54 | 1.86 ** |
| CCND1 | cyclin D1 | 1.54 | −9.09 *** | 3.22 * |
| FN1 | fibronectin 1 | 1.50 | 1.03 | 6.28 ** |
| MMP7 | matrix metallopeptidase 7 | 2.05 | 1.91 | 3.05 ** |
| MYC | v-MYC myelocytomatosis viral oncogene homolog | 2.83 | 1.09 | 4.55 |
| WISP2 | WNT1 inducible signaling pathway protein 2 | −7.69 ** | 1.50 | −4.55 *** |
|
| ||||
| BCL2 | B-cell CLL/lymphoma 2 | 3.54 | −1.54 | 1.86 ** |
| BCL2L1 | BCL2-like 1; Bcl-X | −4.92 | −5.00 ** | −3.33 |
|
| ||||
| GADD45A | growth arrest and DNA-damage-inducible, alpha | 5.22 * | −1.15 | 1.96 |
| IGFBP3 | insulin-like growth factor binding protein 3 | −6.67 * | −1.04 | 1.18 * |
| MDM2 | Mdm2 p53 binding protein homolog (mouse) | 6.83 * | −1.82 | 2.89 |
|
| ||||
| EGR1 | early growth response 1 | −2.70 | −2.50 * | 1.09 |
| FAS | fas (TNF receptor superfamily, member 6) | −2.38 | 1.15 | −2.63 * |
| FOS | FBJ murine osteosarcoma viral oncogene homolog | −2.78 * | 1.56 | −1.59 |
| JUNB | jun B proto-oncogene | −1.01 | −2.56 | −1.33 |
| PTGS2 | rostaglandin-endoperoxide synthase 2 | 1.26 | 1.21 | 8.01 |
|
| ||||
| CDKN1A | cyclin-dependent kinase inhibitor 1A | 1.12 * | 4.01 * | 1.10 |
| CDKN2A | cyclin-dependent kinase inhibitor 2A | 1.89 | 1.35 | −4.17 ** |
| CDKN2B | cyclin-dependent kinase inhibitor 2B | −1.19 | 2.72 | −2.27 |
| CDKN2D | cyclin-dependent kinase inhibitor 2D | 1.31 | −4.55 ** | 1.05 |
|
| ||||
| CDX1 | caudal type homeobox 1 | 1.31 | 2.05 | 1.09 |
| CTSD | cathepsin D | −1.05 | −3.70 | −1.12 |
| EN1 | engrailed homeobox 1 | −1.10 | −2.22 | 1.00 |
| RBP1 | retinol binding protein 1, cellular | 1.68 | −3.03 * | 1.00 |
|
| ||||
| CDK2 | cyclin-dependent kinase 2 | 3.86 | −1.45 | 3.44 ** |
| KLK2 | kallikrein-related peptidase 2 | 6.83 *** | −1.82 | 2.89 |
| TMEPA1 | prostate transmembrane protein, androgen induced 1 | 3.69 | 1.41 | −3.13 *** |
|
| ||||
| BMP4 | bone morphogenetic protein 4 | −2.22 * | −2.38 | −1.67 |
HFFs were stimulated with 1000 particles/cell of ΔgB, ΔgD or ΔgH HSV-1 for six hours and a cDNA microarray corresponding to targets of 19 signalling pathways was used to detect changes in cellular gene expression when compared to mock-infected. Infections and mock infections were carried out in duplicate. A number of signalling pathways were shown to be stimulated by one or more of the entry-defective mutants. These data were used to independently verify changes in expression using real-time PCR.
Independent confirmation of microarray data by real-time PCR.
| Gene | Description | ΔgB | ΔgD | ΔgH |
|
| ||||
| BIRC2 | baculoviral IAP repeat-containing 2 | 3.66 | 1.20 | 2.92 |
| BIRC3 | baculoviral IAP repeat-containing 3 | 4.45 | 1.27 | 3.71 |
| CCL2 | macrophage chemoattractant protein-1 | 2.09 | −1.51 | 3.16 |
| NFKB1 | nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) | 3.54 | 1.13 | 2.61 |
| NFKBIA | nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha | 2.35 | 1.07 | 1.48 |
| NFKBIB | nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta | 2.72 | 1.16 | 1.40 |
| PECAM1 | platelet/endothelial cell adhesion molecule (CD31 antigen) | 3.49 | 1.22 | 4.44 |
| REL | v-REL reticuloendotheliosis viral oncogene homolog (C-REL) | 2.05 | −1.25 | 2.63 |
|
| ||||
| A2M | alpha-2-macroglobulin | 3.54 | 1.77 | 2.55 |
| MMP10 | matrix metallopeptidase 10 | 2.87 | 1.52 | 2.62 |
| NOS2A | nitric oxide synthase 2A | 5.00 | −1.09 | 4.41 |
|
| ||||
| BCL2 | B-cell CLL/lymphoma 2 | 2.86 | −2.33 | 2.13 |
| MMP7 | matrix metallopeptidase 7 | 3.67 | −1.03 | 2.04 |
| MYC | v-MYC myelocytomatosis viral oncogene homolog | 4.53 | −1.04 | 2.67 |
|
| ||||
| BCL2 | B-cell CLL/lymphoma 2 | 2.86 | −2.33 | 2.13 |
| BCL2L1 | BCL2-like 1; Bcl-X | 2.56 | −1.92 | 2.09 |
|
| ||||
| CDK2 | 3.01 | 1.18 | 3.08 |
Note.
*p<0.05.
**p≤0.01.
***p≤0.001.
HFFs were stimulated with 1000 particles/cell of entry-defective HSV-1 and changes in cellular gene expression were detected by real-time PCR at 6 hours post-inoculation. NF-κB responsive genes appear to be up-regulated by binding of either ΔgB or ΔgH virions to the cell. The increase in NF-κB-associated transcripts appears specific as not all targets were differentially regulated. A similar pattern of gene expression is seen for Jak/Stat pathway targets in that ΔgD virions appear to be unable to stimulate signalling whereas ΔgB and ΔgH binding can. MMP7 is only associated with the PI3 Kinase/Akt pathway and coupled with the up-regulation of BCL2, CCND1 and MYC, it would appear that binding may be sufficient to also stimulate this pathway, although not by virions lacking in gD. The Jak/Src pathway only contains two targets on the signalling specific microarray, one of which, BCL2, was associated with other pathways.
Comparison of microarray with real-time PCR data for differentially expressed genes.
| Gene | ΔgB | ΔgD | ΔgH | |||
| Microarray | Real-Time | Microarray | Real-Time | Microarray | Real-Time | |
|
| ||||||
| BIRC2 | 3.66 | 3.85 | 1.20 | 3.98 | 2.92 | −1.01 |
| BIRC3 | 4.45 | 2.88 | 1.27 | 1.00 | 3.71 | 7.71 |
| CCL2 | 2.09 | 2.32 | −1.51 | 1.34 | 3.16 | 2.13 |
| NFKB1 | 3.54 | 2.98 | 1.13 | −1.92 | 2.61 | 3.09 |
| NFKBIA | 2.35 | −1.19 | 1.07 | 1.23 | 1.48 | 2.54 |
| NFKBIB | 2.72 | - | 1.16 | - | 1.40 | - |
| PECAM1 | 3.49 | 4.60 | 1.22 | 1.00 | 4.44 | 3.09 |
| REL | 2.05 | - | −1.25 | - | 2.63 | - |
|
| ||||||
| A2M | 3.54 | 5.07 | 1.77 | 1.79 | 2.55 | 2.23 |
| MMP10 | 2.87 | 1.09 | 1.52 | −1.12 | 2.62 | 2.50 |
| NOS2A | 5.00 | 1.26 | −1.09 | 1.21 | 4.41 | 8.01 |
|
| ||||||
| BCL2 | 2.86 | 1.86 | −2.33 | −1.54 | 2.13 | 1.86 |
| MMP7 | 3.67 | 2.05 | −1.03 | 1.91 | 2.04 | 3.05 |
| MYC | 4.53 | 2.83 | −1.04 | 2.85 | 2.67 | 2.48 |
|
| ||||||
| BCL2 | 2.86 | 1.86 | −2.33 | −1.54 | 2.13 | 1.86 |
| BCL2L1 | 2.56 | 1.42 | −1.92 | −5.00 | 2.09 | −1.18 |
|
| ||||||
| CDK2 | 3.01 | 3.86 | 1.18 | −1.45 | 3.08 | 3.44 |
There was a degree of correlation between the change in expression determined by microarray studies and those confirmed by real-time PCR, particularly for genes under the control of NF-κB. Note: rel and nfkbib were not present on the original signalling-specific microarray, but were included in the real-time analysis, as they are known to be up-regulated as part of the NF-κB feedback mechanism.
Figure 1Kinetics of signalling activation.
(A) An NF-κB luciferase construct was transfected into HFF, which were left to serum-starve for five days. Cells were then mock-infected or inoculated with 1000 particles/cell of entry-defective ΔgH HSV-1 then lysed at the indicated times and assayed for luciferase activity. Error bars are the +/− standard error across triplicate luciferase assays for each biological duplicate. (B) NF-κB, JAK/STAT, JAK/Src and PI3K/Akt-responsive genes that were previously shown to be differentially expressed at 6 hours post-inoculation with ΔgB and ΔgH virions were examined for changes in expression at two-and-a-half hours after inoculation with 1000 particles/cell of ΔgH virions. The induction of JAK/STAT and PI3K/Akt targets is not significantly up-regulated above the two-fold threshold by two-and-a-half hours post-inoculation. A number of NF-κB-associated transcripts are significantly up-regulated, with ccl2 showing a far greater induction at two-and-a-half hours than six hours. Both JAK/Src targets, bcl2 and bcl2l1 are induced to similar levels found at six hours post-inoculation. Error bars are the +/− standard error across triplicate biological replicates.
Interferon response to HSV-1 virion binding.
| Name | Description | ΔgB | ΔgD | ΔgH | MOI 0.01 |
| IFNA1 | interferon, alpha 1 | 2.63 | −1.11 | 2.25 | −1.23 |
| IFNB1 | interferon, beta 1, fibroblast | 3.01 | 2.15 | −1.07 | −1.18 |
| IL29 | interleukin 29 (interferon, lambda 1) | 1.51 | −1.33 | −1.69 | 1.11 |
| ISG54 | IFN-induced protein 54 | 1.20 | 1.57 | −1.54 | −1.45 |
| IRF1 | interferon regulatory factor 1 | −1.21 | 1.07 | 1.36 | 1.00 |
| IRF3 | interferon regulatory factor 3 | 1.14 | −1.10 | 1.05 | 1.08 |
| IRF7 | interferon regulatory factor 7 | 1.19 | 1.03 | −1.05 | −1.23 |
| IRF9 | interferon regulatory factor 9 | −1.23 | 1.03 | 1.44 | −1.33 |
Note.
*p<0.05.
Binding by ΔgB and ΔgH virions up-regulated the expression of IFN-α whereas ΔgB and ΔgD virions were able to stimulate an increase in IFN-β. Infection with wild-type HSV-1 at an MOI of 0.01 was insufficient to cause similar increases in interferon expression. Interferon-stimulated genes were not up-regulated above the two-fold threshold by binding of any of the entry-defective HSV-1 mutants. Wild-type infection at a low MOI was also insufficient to cause in increase in ISG transcripts when compared to mock-infected cells.
Figure 2Effects of virion multiplicity on gene transcription.
Low multiplicities of infection, which may represent physiological conditions, were sufficient to trigger an intracellular signalling response. (A) As the number of inoculated ΔgH particles increases, the number of cycles taken to reach the cycle threshold decreases for the NF-KB-responsive genes nfkbi, ccl2 and rel, indicating an increased abundance of transcript. (B) A similar dose response is seen for the JAK/STAT target nos2a. Error bars are the +/− standard error across triplicate biological replicates.
Figure 3Model for glycoprotein-receptor interactions in the induction of intracellular signalling pathways by HSV-1.
Glycoprotein D acts as the main signalling molecule on the surface of the HSV-1 envelope. gH interacts with αvβ3 integrins to potentially trigger the production of IFN-β, which is known to involve IRF-3 and 7 [48]. Binding by gD to HvEM may lead to the activation of TRAF molecules, which in turn stimulate the NF-κB signaling cascade. This pathway up-regulates a number of cellular genes in addition to augmenting early viral gene expression. NF-κB-responsive genes, birc2 and birc3, have an anti-apoptotic role, but paradoxically, inflammatory mediators such as ccl2 are also up-regulated. gD-induced signalling of the Jak/Stat and Jak/Src pathways also results in the differential expression of genes associated with anti-apoptosis and inflammation. The up-regulation of c-Myc could lead to a corresponding increase in cdk2, which has a role in promoting DNA replication and gene transcription during infection. It should be noted that most signalling cascades have been elucidated in non-fibroblast cells lines, so the role of specific kinases may vary in HFFs.